We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $5.47B
1-Year Est. Return 131.34%
This Fund
S&P 500
This Quarter Est. Return
+39.89%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$5.47B
AUM Growth
+$1.55B
Cap. Flow
+$120M
Cap. Flow %
2.19%
Top 10 Hldgs %
49.14%
Holding
110
New
21
Increased
26
Reduced
17
Closed
14

Top Buys

Rank Stock Value
1
AVLN
Avalyn Pharma
AVLN
+$72.2M
2
HUT
Hut 8
HUT
+$65M
3
SPOT icon
Spotify
SPOT
+$48M
4
FTH
Faeth Therapeutics
FTH
+$45.9M
5
CBRS
Cerebras Systems
CBRS
+$40.5M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$142M
2
KALV
KalVista Pharmaceuticals
KALV
+$96M
3
ERAS icon
Erasca
ERAS
+$55.6M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$37.4M
5
PFGC icon
Performance Food Group
PFGC
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.49%
2 Miscellaneous 14.69%
3 Technology 10.26%
4 Consumer Discretionary 5.22%
5 Financials 4.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
$709M 12.97%
950,000
+600,000
+171% +$435M
MANE
2
Veradermics Inc
MANE
$4.08B
$513M 9.37%
4,168,970
– –
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$2.97B
$326M 5.96%
12,437,000
+110,000
+0.9% +$2.56M
LEGN icon
4
Legend Biotech
LEGN
$4.23B
$204M 3.73%
7,070,000
-511,029
-7% -$13.8M
PVLA
5
Palvella Therapeutics
PVLA
$2.24B
$174M 3.17%
1,135,406
-18,090
-2% -$2.2M
AVBP icon
6
ArriVent BioPharma
AVBP
$1.53B
$157M 2.87%
4,515,531
+114,448
+3% +$3.38M
BNTC icon
7
Benitec Biopharma
BNTC
$427M
$155M 2.83%
11,548,351
– –
BHVN icon
8
Biohaven
BHVN
$2.4B
$153M 2.8%
10,286,937
– –
AMD icon
9
Advanced Micro Devices
AMD
$745B
$149M 2.73%
257,240
– –
RCUS icon
10
Arcus Biosciences
RCUS
$3.84B
$147M 2.69%
4,776,423
-254,570
-5% -$6.29M
TSM icon
11
TSMC
TSM
$2.16T
$145M 2.66%
304,627
+5,920
+2% +$2.4M
NVDA icon
12
NVIDIA
NVDA
$5.52T
$144M 2.64%
720,609
+145,953
+25% +$30M
EYPT icon
13
EyePoint Inc
EYPT
$394M
$119M 2.17%
8,296,375
– –
SYY icon
14
Sysco
SYY
$38.8B
$118M 2.16%
1,411,550
+252,394
+22% +$19.1M
GE icon
15
GE Aerospace
GE
$346B
$116M 2.12%
310,262
– –
IMTX icon
16
Immatics
IMTX
$1.44B
$113M 2.07%
11,190,129
– –
MGM icon
17
MGM Resorts International
MGM
$10.3B
$111M 2.03%
2,325,360
+166,560
+8% +$6.92M
META icon
18
Meta Platforms (Facebook)
META
$1.56T
$99M 1.81%
175,807
+6,100
+4% +$3.73M
CAPR icon
19
Capricor Therapeutics
CAPR
$540M
$98.6M 1.8%
4,092,784
+274,184
+7% +$8.31M
KURA icon
20
Kura Oncology
KURA
$1.17B
$94.1M 1.72%
8,575,422
– –
GLUE icon
21
Monte Rosa Therapeutics
GLUE
$1.23B
$85.9M 1.57%
3,549,539
-677,270
-16% -$12.8M
AVLN
22
Avalyn Pharma
AVLN
$1.57B
$82.4M 1.51%
+2,503,109
New +$72.2M
HD icon
23
Home Depot
HD
$317B
$79.7M 1.46%
226,053
+4,463
+2% +$1.45M
HUT
24
Hut 8
HUT
$10.9B
$77.3M 1.41%
+670,000
New +$65M
COF icon
25
Capital One
COF
$135B
$66.8M 1.22%
333,098
+30,698
+10% +$5.87M
1
2 3 4 5

Similar funds

NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return

Suvretta Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Suvretta Capital Management held 110 positions worth $5.47B, up 40% from $3.92B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Suvretta Capital Management's Q2 2026 filing shows 21 new, 26 increased, 17 reduced and 14 closed positions. Its largest new stake was Avalyn Pharma: 2,503,109 shares worth $82.4M. The largest sale was Apellis Pharmaceuticals, an estimated $142M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 65% a quarter earlier, followed by Miscellaneous and Technology.

  • Suvretta Capital Management's largest Q2 2026 buy was Avalyn Pharma: 2,503,109 shares worth $82.4M.
  • Suvretta Capital Management added most to Spotify in Q2 2026, an estimated $48M increase.
  • Suvretta Capital Management's biggest Q2 2026 reduction was Mineralys Therapeutics, cutting an estimated $37.4M.
  • Suvretta Capital Management fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $142M.
  • Suvretta Capital Management's ten largest holdings make up 49% of its $5.47B portfolio in Q2 2026.
  • Suvretta Capital Management opened 21 new positions and closed 14 in Q2 2026.
  • Suvretta Capital Management's portfolio value rose 40% quarter-over-quarter to $5.47B.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.